Zura Bio Ltd (94E)

Frankfurt


	Symbol		Exchange		Currency
	94E		Frankfurt		EUR	Delayed
	ZURA		NASDAQ		USD	Real-time
	94E		TradeGate		EUR	Delayed

Currency in EUR

2.0800

-0.2800(-11.86%)

Closed13/12

Fair Value

Day's Range

2.0800

2.0800

52 wk Range

1.7300

5.5000

94E Income Statement

Explore the detailed Zura Bio Ltd income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Zura Bio Ltd's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2011

31/12

2012

31/12

2013

31/12

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

Total Revenues

493.33

683.07

1,007.26

1,312.15

1,819.98

Total Revenues Growth

+36.35%

+38.46%

+47.46%

+30.27%

+38.7%

Cost Of Revenues

214.21

325.72

536.6

790.77

1,292.08

Gross Profit

279.12

357.35

470.66

521.38

527.91

Gross Profit Growth

+25.95%

+28.03%

+31.71%

+10.78%

+1.25%

Gross Profit Margin %

56.58%

52.32%

46.73%

39.73%

29.01%

Other Operating Expenses, Total

193.96

257.96

373.32

521.96

642.8

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+23.74%	+33%	+44.72%	+39.82%	+23.15%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	158.76	206.11	287.38	406.51	500.98
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

85.17

99.39

97.34

-0.58

-114.9

Operating Income Growth

+31.27%

+16.71%

-2.06%

-100.59%

-19,778.03%

EBIT Margin %

17.26%

14.55%

9.66%

-0.04%

-6.31%

Net Interest Expenses

0.73

-0.1

-3.53

-20.49

-27.99

Net Interest Expenses Growth

+45.8%

-113.99%

-3,360.78%

-480.54%

-36.57%

Interest Expense, Total

-0.57

-2.1

-7.53

-24.39

-29.69

Interest And Investment Income

1.3

2

4

3.9

1.7

Other Non Operating Expenses, Total

-

-

-

-

-

EBT, Excl. Unusual Items

85.89

99.29

93.81

-21.07

-142.88

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-

-4.04

-

-

-12.5

EBT, Incl. Unusual Items

83.85

89.65

81.43

-26.78

-176.96

EBT, Incl. Unusual Items Growth

+35.4%

+6.91%

-9.16%

-132.88%

-560.88%

EBT, Incl. Unusual Items Margin

17%

13.12%

8.08%

-2.04%

-9.72%

Income Tax Expense

34.3

-9.34

2.95

-8.21

-21.1

Net Income to Company

49.56

98.98

78.48

-18.57

-155.86

Minority Interest

-

-

-

-

-

Net Income

49.56

98.98

78.48

-18.57

-155.86

Net Income Growth

+30.15%

+99.74%

-20.71%

-123.66%

-739.5%

Net Income Margin %

10.05%

14.49%

7.79%

-1.41%

-8.56%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

49.56

98.98

78.48

-18.57

-155.86

Basic EPS - Continuing Operations

0.58

1.15

0.88

-0.2

-1.69

Basic EPS - Continuing Operations Growth

+28.63%

+96.89%

-23.5%

-123.19%

-729.67%

Diluted EPS - Continuing Operations

0.58

1.12

0.85

-0.2

-1.69

Diluted EPS - Continuing Operations Growth

+31.82%

+93.1%

-24.11%

-123.94%

-730.59%

Basic Weighted Average Shares Outstanding

85.07

86.3

89.45

91.25

92.33

Diluted Weighted Average Shares Outstanding

86.14

88.18

92.35

91.25

92.33

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

114.96

139.24

161.48

80.37

-26.77

EBITDA Growth

+26.31%

+21.12%

+15.97%

-50.23%

-133.31%

EBITDA Margin %